Respiratory syncytial virus infection and novel interventions

AC Langedijk, LJ Bont - Nature Reviews Microbiology, 2023 - nature.com
The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in
young children and older adults has gained increased recognition in recent years. Recent …

RSV prevention in all infants: which is the most preferable strategy?

S Esposito, B Abu Raya, E Baraldi, K Flanagan… - Frontiers in …, 2022 - frontiersin.org
Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and
young children that may lead to hospitalizations and a substantial number of outpatient …

[HTML][HTML] Seasonality of respiratory syncytial virus—United States, 2017–2023

S Hamid - MMWR. Morbidity and Mortality Weekly Report, 2023 - cdc.gov
RSV circulation was historically low during 2020–21 and began earlier and continued
longer during 2021–22 than during prepandemic seasons. The 2022–23 season started …

[HTML][HTML] Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on …

JM Jones - MMWR. Morbidity and mortality weekly report, 2023 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting …

Pulmonary fibrosis secondary to COVID-19: a call to arms?

P Spagnolo, E Balestro, S Aliberti… - The Lancet …, 2020 - thelancet.com
As of May 6, 2020, nearly 3· 7 million people have been infected and around 260 000
people have died from coronavirus disease 2019 (COVID-19) worldwide. 1 Almost all …

Off-season RSV epidemics in Australia after easing of COVID-19 restrictions

JS Eden, C Sikazwe, R **e, YM Deng… - Nature …, 2022 - nature.com
Human respiratory syncytial virus (RSV) is an important cause of acute respiratory infection
with the most severe disease in the young and elderly. Non-pharmaceutical interventions …

Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis

SL Ralston, AS Lieberthal, HC Meissner… - …, 2014 - publications.aap.org
This guideline is a revision of the clinical practice guideline,“Diagnosis and Management of
Bronchiolitis,” published by the American Academy of Pediatrics in 2006. The guideline …

Single-dose nirsevimab for prevention of RSV in preterm infants

MP Griffin, Y Yuan, T Takas… - … England Journal of …, 2020 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is the most common cause of lower
respiratory tract infection in infants, and a need exists for prevention of RSV in healthy …

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

H Nair, DJ Nokes, BD Gessner, M Dherani, SA Madhi… - The Lancet, 2010 - thelancet.com
Background The global burden of disease attributable to respiratory syncytial virus (RSV)
remains unknown. We aimed to estimate the global incidence of and mortality from episodes …

The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study

JG Wildenbeest, MN Billard, RP Zuurbier… - The Lancet …, 2023 - thelancet.com
Background Respiratory syncytial virus (RSV) is a major cause of hospitalisation in infants.
The burden of RSV infection in healthy term infants has not yet been established. Accurate …